These pathways can become activated independent from EGFR signaling through mutations in downstream pathway components in cetuximab-resistant CRC, but it is possible that RAC1 overexpression could also contribute to pathway activation, as RAC1 interacts with many EGFR signaling effectors. Here, EGFR is linked to colorectal carcinoma.